Edwards Lifesciences (EW)

Executive Summary

Edwards Lifesciences is the global leader in structural heart disease, particularly transcatheter aortic valve replacement (TAVR), with a strong pipeline in mitral and tricuspid therapies. In 2025, the company completed the spin-off of its critical care business into a separate entity, sharpening its focus on heart valve innovation. Edwards' TAVR portfolio continues to expand with next-generation valves like SAPIEN 3 Ultra RESILIA, leveraging durable tissue technology to extend valve longevity and reduce reintervention rates. The company is also advancing transcatheter mitral and tricuspid interventions, with the PASCAL system for mitral regurgitation gaining adoption and the EVOQUE tricuspid valve replacement system expected to become a key growth driver. With a robust balance sheet and strong market position in an aging population trend, Edwards is well-positioned for sustained revenue growth, though it faces competition from Medtronic and Boston Scientific in TAVR and emerging percutaneous valve markets.

Upcoming Catalysts (preview)

• Q2 2026EVOQUE Tricuspid Valve System FDA Approval85% success
• H2 2026SAPIEN M3 Mitral Valve Replacement CE Mark and Early US Trial Data70% success
• H1 2027Next-Generation TAVR Valve (SAPIEN 4) Early Feasibility Study Initiation90% success